Rockville, MD , April 27, 2018 -- Fibrosarcoma has no definite cause like other sarcomas. However, most of the sarcomas are associated with the genetic mutations. Soft tissue fibrosarcoma is among rare cancer which has no exact cause but carries various risk factors. Undergoing as radiotherapy to treat other cancer is one of the factors that is increasing the risk of fibrosarcoma. Currently, there are very few ways to treat fibrosarcoma with complications involved. Hence, researchers and research institutes around the world are researching for some very effective treatments. Targeted therapies are also being focused on to treat fibrosarcoma. There are also many anti-angiogenesis agents under development and few are in clinical trials. Chemotherapy for soft tissue sarcoma usually involves a combination of various drugs. Hence, companies are researching on new drugs effective in treating soft tissue sarcoma.
Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=353
According to a study by Fact.MR, the global fibrosarcoma market is expected to witness steady growth. The market is likely to register CAGR of 5.5% during the forecast period 2017-2026. The global fibrosarcoma market is also projected to bring in US$ 442.4 million revenue. Fibrosarcoma is increasingly rare as a diagnosis compared to other sarcoma subtypes. Some of the sarcomas are sensitive to chemotherapy, hence ongoing attempts are being done to intensify chemotherapy. However, fibrosarcoma that does not respond to chemotherapy, needs to be treated with other methods but might lead to some side-effects. This is driving the development of new therapies with potential benefits. Below insights show how the global fibrosarcoma market will perform in the coming years.
5 Forecast Highlights on Global Fibrosarcoma Market
1- North America is expected to remain dominant in the global fibrosarcoma market during the forecast period 2017-2026. Well-developed healthcare infrastructure in North America is one of the factors boosting the growth of fibrosarcoma treatment in the region. Technological advancement is also resulting in the development of advanced cancer treatment drugs. Moreover, increasing population suffering from diabetes, overweight and depression are also leading towards high possibilities of cancer.
2- Europe and Asia Pacific Excluding Japan (APEJ) are also expected to witness growth in the diagnoses and treatment of fibrosarcoma due to the increasing investments in the research and development activities for treatment of various cancers.
To know more about Fibrosarcoma Market Trends, check the link - https://www.factmr.com/report/353/fibrosarcoma-market
3- Chemotherapy is expected to be the most preferred treatment for fibrosarcoma. By the end of 2026, chemotherapy is projected to reach close to US$ 200 million revenue.
4- Hospitals are expected to be the largest end-users in the global fibrosarcoma market. Hospitals are projected to reach nearly US$ 200 million revenue by the end of 2026.
5- Among various distribution channels, hospital pharmacy is expected to emerge as the largest distribution channel during the forecast period 2017-2026. Accounting for nearly half of the revenue share, hospital pharmacies are projected to exceed US$ 100 million revenue towards the end of 2026.
The report also offers an in-depth analysis of the leading market players in the global market for fibrosarcoma, which will remain active through 2026. These include companies such as Johnson & Johnson, Pfizer Inc., Eli Lilly and Company, Baxter International Inc., Novartis AG, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Bristol-Myers Squibb Company, Celon Laboratories Limited, and Cadila Pharmaceuticals Limited.
To Buy Fibrosarcoma Market Report, Check the link- https://www.factmr.com/checkout/353/S
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Mr. Rohit Bhisey
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: [email protected]
Web: https://www.factmr.com/
Read Industry News at - https://www.industrynewsanalysis.com/


Bain Capital Exits Kioxia After AI-Fueled Valuation Surge
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 



